TRX 518

Drug Profile

TRX 518

Alternative Names: Anti-GITR monoclonal antibody - Leap Therapeutics; Anti-TNFRSF18 monoclonal antibody; TRX518

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator Tolerx
  • Developer GITR Inc; Leap Therapeutics
  • Class Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action Glucocorticoid receptor agonists; T lymphocyte stimulants; Tumour necrosis factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Malignant melanoma; Solid tumours
  • No development reported Viral infections

Most Recent Events

  • 03 Apr 2017 Pharmacodynamics data from a phase I trial in Malignant melanoma presented at the Annual Meeting of American Association for Cancer Research (AACR-2017)
  • 07 Jun 2016 GITR completes a phase-I clinical trial in Solid tumours (Second-line therap or greater, Inoperable/Unresectable, Late-stage disease) in USA (IV) (NCT01239134)
  • 21 Jan 2016 HealthCare Pharmaceuticals and GITR Inc. merge to form Leap Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top